PMC:7283670 / 77261-77703
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T269 | 429-433 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T419 | 97-106 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T420 | 167-176 | Disease | denotes | Infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T663 | 427-433 | http://purl.obolibrary.org/obo/CL_0000084 | denotes | T cell |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T692 | 0-442 | Sentence | denotes | Safety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response |